![Pharmacology for the Primary Care Provider - E-Book Pharmacology for the Primary Care Provider - E-Book](https://123library.org/images/books/140414.png?w=254&h=360&fit=&c=2&assets_cache=20240419223356)
BOOK
Pharmacology for the Primary Care Provider - E-Book
Marilyn Winterton Edmunds | Maren Stewart Mayhew
(2013)
Additional Information
Book Details
Abstract
Written by and for nurse practitioners, and also suitable for physician’s assistants, Pharmacology for the Primary Care Provider, 4th Edition focuses on what you need to know to safely and effectively prescribe drugs for primary care. An emphasis on patient teaching helps you gain patient adherence to prescribed drug regimens, and guidelines for health promotion help in maintaining and improving your patients’ health. Now in full color, this edition expands the book's emphasis on the QSEN priorities of safety and evidence-based practice, and adds coverage of new drugs, new drug classes, and new therapeutic drug uses. Written by leading nurse practitioner authorities Marilyn Winterton Edmunds and Maren Stewart Mayhew, Pharmacology for the Primary Care Provider teaches principles of pharmacotherapeutics using today’s most commonly used drugs.
- A Key Drugs focus highlights the most commonly used and most representative drugs of each major drug class — with particular emphasis on the top 100 most commonly prescribed drugs.
- Emphasis on patient teaching helps you communicate with patients and family caregivers to promote adherence to the drug regimen.
- Emphasis on health promotion describes how to help patients stay well and improve their health, including coverage of immunizations and biologicals, vitamins, weight management, and smoking cessation.
- Evidence-Based Decision-Making and Treatment Guidelines chapter (11) provides practical guidelines for using the best current research evidence to make decisions about the care of individual patients.
- Extensive coverage of drug therapy for special populations such as geriatric and pediatric patients includes considerations related to age, pregnancy, race, and other factors.
- UNIQUE! Coverage of prescriptive practice includes topics such as prescriptive authority, role implementation, and the role of nurses (NPs, CNMs, CRNAs, and CNSs) and physician assistants in writing prescriptions.
- NEW! Full-color design and illustrations highlight the most important content.
- DRUG UPDATES reflect the latest FDA-approved drugs, drug classes, and therapeutic uses.
- Expanded emphasis on the QSEN priorities of safety and evidence-based practice helps you eliminate drug prescribing errors with color-highlighted Safety Alerts! and NEW Clinical Practice Alerts!
- NEW section on male hormone replacement therapies adds coverage of men to that for women.
- Updated evidence-based prescribing information reflects the latest national clinical practice guidelines and evidence-based treatment guidelines, including the latest clinical treatment guidelines for diabetes.
- NEW! Complementary and Alternative Products tables highlight interactions with drugs, and are emphasized with a distinctive icon.
- Updated Drug Overview tables are enhanced with color as well as Top 100 icons that highlight the most commonly prescribed drugs.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front\rCover | Cover | ||
Table of Contents | IFC | ||
Evolve Page | ii | ||
Pharmacology for the Primary Care Provider\r | iii | ||
Copyright | iv | ||
Contributors | v | ||
Reviewers | vi | ||
Preface | vii | ||
Special Features | vii | ||
Organization | vii | ||
Contents | ix | ||
UNIT 1 -\rFoundations of Prescriptive Practice | 1 | ||
Chapter 1 - Prescriptive Authority and Role Implementation: Tradition vs. Change | 1 | ||
Traditional Provision of Primary Care | 1 | ||
Importance of Prescriptive Authority in Health Care Delivery | 2 | ||
Research on Prescriptive Practice of Physicians | 2 | ||
Problems in the Prescribing Practice of Physicians | 3 | ||
Summary | 4 | ||
Chapter 2 - Historical Review of Prescriptive Authority: The Role of Nurses (NPs, CNMs, CRNAs, and CNSs) and Physician Assistants | 5 | ||
The Prescriptive Authority of Nurses | 6 | ||
Prescriptive Authority and the Physician’s Assistant | 15 | ||
Acknowledgments | 19 | ||
UNIT 2 -\rPharmacokinetics and Pharmacodynamics | 21 | ||
Chapter 3 - General Pharmacokinetic and Pharmacodynamic Principles\r | 21 | ||
Drug Nomenclature | 21 | ||
Pharmacokinetics | 21 | ||
Pharmacodynamics | 32 | ||
Summary | 49 | ||
Chapter 4 - Special Populations: Geriatrics | 50 | ||
Functional Assessment | 50 | ||
Process Model of Prescribing for the Elderly | 58 | ||
Chapter 5 - Special Populations: Pediatrics | 60 | ||
Effect of Disease on Drug Processes in Children | 63 | ||
Choosing a Drug Regimen | 64 | ||
Adverse Drug Reactions in Children | 64 | ||
Calculations of Pediatric Dosages | 64 | ||
Special Compliance Problems in Children | 69 | ||
Summary | 69 | ||
Chapter 6 - Special Populations: Pregnant and Nursing Women | 70 | ||
Specific Infections of Concern | 77 | ||
Known Hazards to Mothers and Their Children | 82 | ||
Drugs in Breastfeeding Mothers | 84 | ||
Chapter 7 - Over-the-Counter Medications | 88 | ||
Extent of OTC Medication Use | 88 | ||
Advantages and Disadvantages of OTC Use | 90 | ||
How Can the Primary Care Provider Be Helpful to Patients Who Are Taking OTC Medications? | 90 | ||
Chapter 8 - Complementary and Alternative Therapies\r | 93 | ||
Defining Complementary and Alternative Therapies | 93 | ||
Complementary Therapies and Herbal Medicine | 95 | ||
Drug–Herb Interactions | 98 | ||
Patient Variables | 100 | ||
UNIT 3 -\rThe Art and Scienceof Pharmacotherapeutics | 103 | ||
Chapter 9 - Establishing the Therapeutic Relationship | 103 | ||
Failure of the Therapeutic Relationship | 109 | ||
Chapter 10 - Practical Tips on Writing Prescriptions | 112 | ||
Who May Write Prescriptions? | 112 | ||
Drug Schedules | 113 | ||
Components of the Traditional Prescription | 114 | ||
Electronic Drug Prescriptions or E-Sign | 116 | ||
Drug Prescribing Etiquette | 116 | ||
Avoiding Mistakes | 117 | ||
Administrative Concerns | 119 | ||
Preventing Problems in Drug Use | 121 | ||
Good Communication and Developing a Positive Relationship with the Pharmacist | 122 | ||
Chapter 11 - Evidence-Based Decision Making and Treatment Guidelines | 123 | ||
Critical Thinking | 123 | ||
Decision Making | 125 | ||
Evidence-Based Medicine | 131 | ||
Clinical Guidelines | 135 | ||
Chapter 12 - Design and Implementation of Patient Education | 139 | ||
Evaluation of Learning | 144 | ||
UNIT 4 -\rTopical Agents | 149 | ||
Chapter 13 - Dermatologic Agents\r | 149 | ||
Therapeutic Overview of Dermatologic Agents | 150 | ||
Mechanism of Action | 152 | ||
Treatment Principles | 152 | ||
Topical Corticosteroids | 153 | ||
Therapeutic Overview of Topical Corticosteroids | 153 | ||
Mechanism of Action | 154 | ||
Treatment Principles | 154 | ||
UNIT 5 -\rRespiratory Agents | 185 | ||
Chapter 15 - Upper Respiratory Agents \r | 185 | ||
Therapeutic Overview of Upper Respiratory Infection and Allergic Rhinitis | 187 | ||
Mechanism of Action | 187 | ||
Treatment Principles | 188 | ||
Specific Drugs | 194 | ||
Chapter 16 - Asthma and Chronic Obstructive Pulmonary Disease Medications | 204 | ||
Therapeutic Overview of Asthma | 205 | ||
Therapeutic Overview of Chronic Obstructive Pulmonary Disease | 207 | ||
Mechanism of Action | 208 | ||
Treatment Principles of Asthma | 209 | ||
Treatment Principles of COPD | 212 | ||
Specific Drugs | 216 | ||
UNIT 6 -\rCardiovascular Agents | 225 | ||
Chapter 17 - Hypertension and Miscellaneous Antihypertensive Medications\r | 225 | ||
Therapeutic Overview of Hypertension | 225 | ||
Mechanism of Action | 228 | ||
Treatment Principles | 229 | ||
Specific Drugs | 233 | ||
Chapter 18 - Coronary Artery Disease and Antianginal Medications | 236 | ||
Therapeutic Overview of Coronary Artery Disease | 236 | ||
Mechanism of Action | 239 | ||
Treatment Principles | 240 | ||
Specific Drugs | 244 | ||
Chapter 19 - Heart Failure and Digoxin | 247 | ||
Therapeutic Overview of Chronic Heart Failure | 247 | ||
Mechanism of Action | 248 | ||
Treatment Principles | 250 | ||
Specific Drugs | 254 | ||
Chapter 20 - β-Blockers | 256 | ||
Mechanism of Action | 256 | ||
Treatment Principles | 258 | ||
Specific Drugs | 261 | ||
Chapter 21 - Calcium Channel Blockers | 265 | ||
Therapeutic Overview | 265 | ||
Mechanism of Action | 265 | ||
Treatment Principles | 267 | ||
Specific Drugs | 269 | ||
Chapter 22 - ACE Inhibitors and Angiotensin Receptor Blockers | 273 | ||
Therapeutic Overview | 274 | ||
Mechanism of Action | 274 | ||
Treatment Principles | 275 | ||
Specific Drugs | 278 | ||
Chapter 23 - Antiarrhythmic Agents | 281 | ||
Therapeutic Overview of Arrhythmias | 281 | ||
Mechanism of Action | 284 | ||
Treatment Principles | 285 | ||
Specific Drugs | 288 | ||
Chapter 24 - Antihyperlipidemic Agents | 293 | ||
Therapeutic Overview | 294 | ||
Mechanism of Action | 295 | ||
Treatment Principles | 296 | ||
Specific Drugs | 301 | ||
Chapter 25 - Agents That Act on Blood | 307 | ||
Therapeutic Overview | 309 | ||
Mechanism of Action | 310 | ||
Treatment Principles | 312 | ||
Specific Drugs | 319 | ||
UNIT 7 -\rGastrointestinal Agents | 327 | ||
Chapter 26 - Antacids and the Management of GERD | 327 | ||
Mechanism of Action | 328 | ||
Treatment Principles | 328 | ||
Specific Drugs | 331 | ||
Chapter 27 - Histamine2-Blockers and Proton Pump Inhibitors | 333 | ||
Therapeutic Overview | 333 | ||
Mechanism of Action | 335 | ||
Treatment Principles | 336 | ||
Specific Drugs | 337 | ||
Chapter 28 - Laxatives | 340 | ||
Therapeutic Overview | 341 | ||
Mechanism of Action | 342 | ||
Treatment Principles | 342 | ||
Specific Drugs | 346 | ||
Chapter 29 - Antidiarrheals | 351 | ||
Therapeutic Overview | 351 | ||
Mechanism of Action | 352 | ||
Treatment Principles | 353 | ||
Specific Drugs | 354 | ||
Chapter 30 - Antiemetics | 356 | ||
Therapeutic Overview | 356 | ||
Mechanism of Action | 357 | ||
Treatment Principles | 358 | ||
Specific Drugs | 359 | ||
Chapter 31 - Medications for Irritable Bowel Syndrome and Other Gastrointestinal Problems | 362 | ||
Irritable Bowel Syndrome | 362 | ||
Therapeutic Overview of Irritable Bowel Syndrome | 362 | ||
Mechanism of Action | 363 | ||
Treatment Principles | 363 | ||
Specific Drugs | 365 | ||
UNIT 8 -\rRenal/Genitourinary Agents | 369 | ||
Chapter 32 - Diuretics\r | 369 | ||
UNIT 9\r- Musculoskeletal Agents | 399 | ||
Chapter 35 - Acetaminophen\r | 399 | ||
Therapeutic Overview | 399 | ||
Mechanism of Action | 400 | ||
Treatment Principles | 400 | ||
Specific Drugs | 401 | ||
Chapter 36 - Aspirin and Nonsteroidal Antiinflammatory Medications | 403 | ||
Therapeutic Overview | 404 | ||
Mechanism of Action | 405 | ||
Treatment Principles | 407 | ||
Chapter 37 - Disease-Modifying Antirheumatic Medications and Immune Modulators | 415 | ||
Mechanism of Action | 416 | ||
Treatment Principles | 417 | ||
Specific Drugs | 420 | ||
Chapter 38 - Gout Medications | 422 | ||
Therapeutic Overview | 422 | ||
Mechanism of Action | 423 | ||
Treatment Principles | 424 | ||
Specific Drugs | 426 | ||
Chapter 39 - Osteoporosis Treatment | 429 | ||
Therapeutic Overview | 430 | ||
Mechanism of Action | 432 | ||
Treatment Principles | 433 | ||
Specific Drugs | 438 | ||
Chapter 40 - Muscle Relaxants | 442 | ||
Therapeutic Overview | 442 | ||
Mechanism of Action | 443 | ||
Treatment Principles | 444 | ||
Specific Drugs | 445 | ||
UNIT 10 -\rCentral Nervous System Agents | 447 | ||
Chapter 41 - Medications for Attention-Deficit/Hyperactivity Disorder\r | 447 | ||
Therapeutic Overview | 448 | ||
Mechanism of Action | 450 | ||
Treatment Principles | 450 | ||
Specific Drugs | 452 | ||
Chapter 42 - Medications for Dementia | 457 | ||
Therapeutic Overview | 457 | ||
Mechanism of Action | 458 | ||
Treatment Principles | 458 | ||
Specific Drugs | 460 | ||
Chapter 43 - Analgesia and Pain Management | 463 | ||
Therapeutic Overview | 464 | ||
Mechanism of Action | 466 | ||
Treatment Principles | 467 | ||
Specific Drugs | 470 | ||
Chapter 44 - Migraine Medications | 477 | ||
Therapeutic Overview | 477 | ||
Mechanism of Action | 479 | ||
Treatment Principles | 480 | ||
Specific Drugs | 484 | ||
Chapter 45 - Antiepileptics | 488 | ||
Therapeutic Overview | 490 | ||
Mechanism of Action | 490 | ||
Treatment Principles | 491 | ||
Specific Drugs | 496 | ||
Chapter 46 - Antiparkinson Agents | 503 | ||
Therapeutic Overview | 503 | ||
Mechanism of Action | 505 | ||
Treatment Principles | 506 | ||
Specific Drugs | 508 | ||
UNIT 11 -\rPsychotropic Agents | 517 | ||
Chapter 47 - Antidepressants\r | 517 | ||
Therapeutic Overview | 519 | ||
Mechanism of Action | 521 | ||
Treatment Principles | 523 | ||
Specific Drugs | 530 | ||
Chapter 48 - Antianxiety and Antiinsomnia Agents | 538 | ||
Therapeutic Overview | 539 | ||
Mechanism of Action | 541 | ||
Treatment Principles of Antianxiety Agents | 542 | ||
Treatment Principles of Antiinsomnia Agents | 543 | ||
Treatment Principles of Benzodiazepines | 544 | ||
Specific Drugs | 545 | ||
Chapter 49 - Antipsychotics | 551 | ||
Therapeutic Overview | 552 | ||
Mechanism of Action | 554 | ||
Treatment Principles | 556 | ||
Specific Drugs | 558 | ||
Chapter 50 - Substance Abuse | 565 | ||
Therapeutic Overview | 565 | ||
Mechanism of Action and Effects of Alcohol Treatment | 566 | ||
Treatment Principles | 567 | ||
Specific Drugs | 569 | ||
UNIT 12 -\rEndocrine Agents | 573 | ||
Chapter 51 - Glucocorticoids\r | 573 | ||
Therapeutic Overview | 573 | ||
Mechanism of Action | 574 | ||
Treatment Principles | 575 | ||
Specific Drugs | 577 | ||
Chapter 52 - Thyroid Medications | 580 | ||
Thyroid Supplements | 580 | ||
Therapeutic Overview | 580 | ||
Mechanism of Action | 581 | ||
Treatment Principles | 582 | ||
Specific Drugs | 583 | ||
Thyroid Suppressants | 584 | ||
Therapeutic Overview | 585 | ||
Mechanism of Action | 585 | ||
Treatment Principles | 585 | ||
Specific Drugs | 587 | ||
Adjunctive (Diagnostic Tool for Thyroid Cancer) | 588 | ||
Specific Drugs | 588 | ||
Chapter 53 - Diabetes Mellitus Agents | 589 | ||
Therapeutic Overview | 590 | ||
Mechanism of Action | 592 | ||
Treatment Principles | 594 | ||
Specific Drugs | 599 | ||
UNIT 13 -\rReproductive System Medications | 605 | ||
Chapter 54 - Contraceptives\r | 605 | ||
Therapeutic Overview | 609 | ||
Mechanism of Action | 612 | ||
Treatment Principles | 617 | ||
Specific Drugs | 624 | ||
Chapter 55 - Hormone Replacement Therapy | 628 | ||
Hormone Replacement Therapy for Women | 629 | ||
Therapeutic Overview of Hormone Therapy | 630 | ||
Mechanism of Action | 632 | ||
Treatment Principles | 633 | ||
Specific Drugs | 636 | ||
Male Reproductive Hormone Replacement\r | 642 | ||
Therapeutic Overview of Hypogonadism | 642 | ||
Mechanism of Action | 643 | ||
Treatment Principles | 643 | ||
Specific Drugs | 644 | ||
Chapter 56 - Drugs for Breast Cancer | 646 | ||
Therapeutic Overview | 646 | ||
Mechanism of Action | 647 | ||
Treatment Principles | 647 | ||
Specific Drugs | 648 | ||
UNIT 14 -\rAntiinfectives | 651 | ||
Chapter 57 - Principles for Prescribing Antiinfectives\r | 651 | ||
Therapeutic Overview | 651 | ||
Mechanism of Action | 655 | ||
Treatment Principles | 655 | ||
Chapter 58 - Treatment of Specific Infections and Miscellaneous Antibiotics | 658 | ||
Specific Drugs | 667 | ||
Chapter 59 - Penicillins | 670 | ||
Therapeutic Overview | 672 | ||
Mechanism of Action | 672 | ||
Treatment Principles | 673 | ||
Specific Drugs | 674 | ||
Chapter 60 - Cephalosporins | 677 | ||
Therapeutic Overview | 678 | ||
Mechanism of Action | 678 | ||
Treatment Principles | 678 | ||
Specific Drugs | 681 | ||
Chapter 61 - Tetracyclines | 683 | ||
Therapeutic Overview | 683 | ||
Mechanism of Action | 683 | ||
Treatment Principles | 684 | ||
Specific Drugs | 685 | ||
Chapter 62 - Macrolides | 687 | ||
Allergy | 687 | ||
Resistance | 687 | ||
Mechanism of Action | 688 | ||
Treatment Principles | 688 | ||
Specific Drugs | 689 | ||
Chapter 63 - Fluoroquinolones | 692 | ||
Therapeutic Overview | 692 | ||
Mechanism of Action | 693 | ||
Treatment Principles | 693 | ||
Specific Drugs | 695 | ||
Chapter 64 - Aminoglycosides | 697 | ||
Therapeutic Overview | 698 | ||
Mechanism of Action | 698 | ||
Treatment Principles | 698 | ||
Specific Drugs | 699 | ||
Chapter 65 - Sulfonamides | 701 | ||
Therapeutic Overview | 701 | ||
Mechanism of Action | 702 | ||
Treatment Principles | 702 | ||
Specific Drugs | 703 | ||
Chapter 66 - Antitubercular Agents | 705 | ||
Therapeutic Overview | 705 | ||
Mechanism of Action | 708 | ||
Treatment Principles | 708 | ||
Specific Drugs | 710 | ||
Chapter 67 - Antifungals | 716 | ||
Therapeutic Overview | 717 | ||
Mechanism of Action | 718 | ||
Treatment Principles | 718 | ||
Specific Drugs | 720 | ||
Chapter 68 - Antiretroviral Medications | 725 | ||
Therapeutic Overview of HIV and Retroviruses | 726 | ||
Mechanism of Action | 727 | ||
Treatment Principles | 730 | ||
Specific Drugs | 734 | ||
Chapter 69 - Antivirals and Antiprotozoal Agents | 739 | ||
Therapeutic Overview of Viruses and Protozoa | 739 | ||
Mechanism of Action | 740 | ||
Treatment Principles | 741 | ||
Specific Drugs | 743 | ||
UNIT 15 -\rHealth Promotion | 749 | ||
Chapter 70 - The Immune System and Immunizations | 749 | ||
Therapeutic Overview | 750 | ||
Mechanism of Action | 753 | ||
Therapeutic Overview | 753 | ||
Treatment Principles | 754 | ||
Specific Vaccines | 758 | ||
Chapter 71 - Weight Management | 771 | ||
Therapeutic Overview | 771 | ||
Mechanism of Action | 774 | ||
Treatment Principles | 774 | ||
Specific Drugs | 778 | ||
Chapter 72 - Smoking Cessation | 779 | ||
Therapeutic Overview | 779 | ||
Mechanism of Action | 780 | ||
Treatment Principles | 780 | ||
Specific Drugs | 791 | ||
Chapter 73 - Vitamins and Minerals | 793 | ||
Vitamins | 801 | ||
Minerals | 802 | ||
Reading and References | 817 | ||
Index | 839 | ||
Drug Scheduling and FDA\rPregnancy Categories | IBC1 | ||
Top 100 Generic and Brand-Name Drugs by Units in 2012 | IBC2 |